In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today ...
Please provide your email address to receive an email when new articles are posted on . Patients classified with highest risk who were treated with ART had a 50% decrease in metastatic disease ...
Study finds that using DecisionDx-SCC to guide patient selection for adjuvant radiation therapy (ART), identifying patients with cutaneous squamous cell carcinoma (SCC) who can safely forgo the ...
FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of ...
Castle's DecisionDx squamous cell carcinoma (SCC) test tries to identify the risk of metastasis in SCC patients with one or more risk factors, based on 40 genes within tumor tissue. Wisconsin ...
Hosted on MSN
Castle Biosciences raises 2025 revenue guidance to $310M–$320M following strong Q2 execution and test volume growth
The company raised 2025 total revenue guidance to $310 million–$320 million. Stokes explained that “our normalized revenue growth range in 2025 would be approximately 21% to 26%” when excluding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback